Market Place
Sourcing Support
New York biotech files for bankruptcy
22 Nov 2024 //
FIERCE BIOTECH
Seelos Therapeutics Announces Delisting From Nasdaq To OTC Market
15 Oct 2024 //
PR NEWSWIRE
Seelos Therapeutics Announces 1-for-16 Reverse Stock Split
25 Sep 2024 //
PR NEWSWIRE
Seelos Prices $1.1M Registered Direct & Private Placement
16 May 2024 //
PR NEWSWIRE
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split
14 May 2024 //
PR NEWSWIRE
Seelos Provides Update on Top-Line Results ALS Study SLS-005 (IV Trehalose)
19 Mar 2024 //
PR NEWSWIRE
Seelos’ sugar therapy fails to improve ALS severity in ph. 2/3
19 Mar 2024 //
FIERCE BIOTECH
Seelos Therapeutics, Inc. Releases Letter to its Stockholders
22 Dec 2023 //
PR NEWSWIRE
Seelos Therapeutics Announces Closing of Public Offering
01 Dec 2023 //
PR NEWSWIRE
Seelos Therapeutics Announces Proposed Public Offering
28 Nov 2023 //
PR NEWSWIRE
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
28 Nov 2023 //
PR NEWSWIRE
Seelos Announces the Selection of SLS-002 for Inclusion in DoD`s Platform Trial
27 Nov 2023 //
PR NEWSWIRE
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split
24 Nov 2023 //
PR NEWSWIRE
Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer`s Disease
27 Oct 2023 //
PR NEWSWIRE
Seelos Therapeutics Retains Canaccord Genuity
17 Oct 2023 //
PR NEWSWIRE
Seelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005
27 Sep 2023 //
PR NEWSWIRE
Seelos Therapeutics Announces Registered Direct Offering of Common Stock
21 Sep 2023 //
PR NEWSWIRE
Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study
20 Sep 2023 //
PR NEWSWIRE
Seelos` stock plunges by 75% after ketamine drug for suicide prevention fails
20 Sep 2023 //
ENDPTS
Seelos Therapeutics Provides Second Quarter 2023 Clinical Update
14 Aug 2023 //
PR NEWSWIRE
Seelos Therapeutics to Participate in Two Upcoming Healthcare Conferences
22 May 2023 //
PR NEWSWIRE
Seelos Therapeutics Provides Clinical Update and Reports 1Q 2023 FYR Results
15 May 2023 //
PR NEWSWIRE
Seelos Therapeutics Doses the First ALS Patient with SLS-005
04 Apr 2023 //
PR NEWSWIRE
Seelos `temporarily` stops study in rare neuro disorder for business reasons
30 Mar 2023 //
ENDPTS
Seelos Therapeutics Announces Business Update on its Key Programs
29 Mar 2023 //
PR NEWSWIRE
Seelos Therapeutics Announces Registered Direct Offering of Common Stock
10 Mar 2023 //
PR NEWSWIRE
Seelos Therapeutics to Participate in 43rd Annual Cowen Health Care Conference
15 Feb 2023 //
PR NEWSWIRE
Seelos Therapeutics to Present a Poster on SLS-004 at the 11th Annual Summit
10 Feb 2023 //
PR NEWSWIRE
Seelos Therapeutics Doses First Patients in an Ethnobridging Study with SLS-002
06 Feb 2023 //
PR NEWSWIRE
Seelos to Participate the 12th Annual LifeSci Partners Corporate Access Event
22 Dec 2022 //
PRNEWSWIRE
Seelos Announces Data Showing Downregulation of Alpha Synuclein Study of SLS-004
15 Dec 2022 //
PRNEWSWIRE
Seelos Therapeutics Releases the Itinerary for Conference to be Held in Dec
08 Dec 2022 //
PRNEWSWIRE
Seelos Therapeutics to Hold a Research and Development Update Conference
23 Nov 2022 //
PRNEWSWIRE
Seelos to Participate in the Guggenheim 4th Annual Immunology and Neurology Day
07 Nov 2022 //
PRNEWSWIRE
Seelos Therapeutics to Sponsor and Participate in Wonderland
27 Oct 2022 //
PRNEWSWIRE
Seelos doses first subject in Phase II/III spinocerebellar ataxia trial
26 Oct 2022 //
CLINICALTRIALSARENA
Seelos Doses First Patient in a Registrational Phase II/III study of SLS-005
25 Oct 2022 //
PRNEWSWIRE
Seelos to Participate in the Guggenheim Nantucket Therapeutics Conference
09 Sep 2022 //
PRNEWSWIRE
Seelos Therapeutics to Participate in Two Upcoming Psychedelic Conferences
30 Aug 2022 //
PRNEWSWIRE
Seelos gets R&D grant from The Michael J. Fox Foundation for SLS-004
25 Aug 2022 //
PHARMABIZ
Seelos Therapeutics Receives R&D Grant for Parkinson`s Research for SLS-004
24 Aug 2022 //
PRNEWSWIRE
Seelos doses first subject in ALS basket trial in Australia
19 Jul 2022 //
CLINICALTRIALSARENA
Seelos Tx Doses First Patient in an Open Label Basket Study of SLS-005 in ALS
18 Jul 2022 //
PRNEWSWIRE
Seelos Receives a Notice of Allowance for an Additional Patent for SLS-007
18 May 2022 //
PRNEWSWIRE
Seelos Therapeutics to Participate in the 2022 Jefferies Conference
12 May 2022 //
PRNEWSWIRE
Seelos Therapeutics to Participate in the B. Riley Securities` Virtual Neuro
22 Apr 2022 //
PRNEWSWIRE
Seelos Tx Receives an Acknowledgement Letter of Trial Notification for SLS-005
08 Mar 2022 //
PRNEWSWIRE
Seelos Tx says Year-End 2021 Business and Update
07 Mar 2022 //
PRNEWSWIRE
Seelos gets Japenese patent covering composition of matter for SLS-007
08 Dec 2021 //
PHARMABIZ
Seelos Raises $20M in Private Placement of Senior Secured Convertible Note
24 Nov 2021 //
PRNEWSWIRE
Seelos Acquires Exc. License of iX Biopharma`s Wafer-Based Delivery Platform
24 Nov 2021 //
PRNEWSWIRE
Seelos Therapeutics to Present at the 4th Annual ALS ONE Research Symposium
10 Nov 2021 //
PRNEWSWIRE
Seelos Therapeutics to Participate in Two Investor Conferences in September
09 Sep 2021 //
PRNEWSWIRE
Seelos Announces Appointment of Margaret Dalesandro to the Board of Directors
02 Sep 2021 //
PRNEWSWIRE
Seelos Therapeutics Announces Senior Management Appointments
01 Sep 2021 //
PRNEWSWIRE
Seelos Therapeutics Announces Mid-Year 2021 Business and Clinical Update
09 Aug 2021 //
PRNEWSWIRE
Seelos Therapeutics Announces Mid-Year 2021 Business and Clinical Update
09 Aug 2021 //
PRNEWSWIRE
Seelos Therapeutics to Participate in Two Investor Conferences in August
14 Jul 2021 //
PRNEWSWIRE
Seelos Therapeutics to Participate in Two Investor Conferences in August
14 Jul 2021 //
PRNEWSWIRE
